Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SV-BR-1-GM · 3 trials · 6 indications
To evaluate the effect of the Bria-IMT regimen in combination with Check Point Inhibitor (CPI) on overall survival (OS) compared to treatment of physician's choice (TPC) chemotherapy in patients with metastatic breast cancer with no approved alternative therapies available as per the Inclusion criteria.
To evaluate the safety of SV-BR-1-GM as assessed by: o Adverse Events (AEs), including Serious Adverse Events (SAEs)
To evaluate the safety of SV-BR-1-GM as assessed by: o The Proportion of Patients with Abnormalities in Safety Laboratory Parameters
To evaluate the safety of SV-BR-1-GM as assessed by: o Electrocardiograms (ECG) with measurement of the QT interval
To evaluate the number of patients with toxicity events while on SV-BR-1-GM, as defined by the Common Terminology Criteria for Adverse Events (CTCAE)
| Arm | Type | Description |
|---|---|---|
| Bria-IMT Regimen + CPI | EXPERIMENTAL | The Bria-IMT regimen: Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site |
| Treatment of Physician's Choice | ACTIVE_COMPARATOR | TPC consists of eribulin, carboplatin, capecitabine, gemcitabine, vinorelbine or taxanes in accordance with the investigators' and institutional standard of care. The specific details of the selected regimen must include every detail of administration including frequency, sequencing (for multi-agent regimens), duration of infusion or oral administration, planned dose, dose prescribed, dose administered, dose adjustments after initial prescription or start of TPC treatment, and any other change in TPC from its initial election prior to randomization. |
| Bria-IMT Regimen Alone | EXPERIMENTAL | The Bria-IMT regimen: Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site |
| SV-BR-1-GM, retifanlimab combination original sequence | EXPERIMENTAL | Subjects will be treated with the SV-BR-1-GM regimen in combination with retifanlimab with cycles every 3 weeks |
| SV-BR-1-GM, retifanlimab combination alternative sequence | EXPERIMENTAL | Subjects will be treated with the SV-BR-1-GM regimen in combination with retifanlimab as follows: Cycle 1: SV-BR-1-GM only Cycle 2: resume retifanlimab on Day 2±1 Cycle 3 and beyond: retifanlimab can be administered on Day -2, Day 0, 1, 2, or 3. |
| SV-BR-1-GM Monotherapy | EXPERIMENTAL | Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites \~2 and \~4 days after SV-BR-1-GM inoculation |
| Name | Type | Description |
|---|---|---|
| SV-BR-1-GM | BIOLOGICAL | SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity |
| Cyclophosphamide | DRUG | Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations. |
| Interferon infiltration of the inoculation site | DRUG | Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered. |
| Retifanlimab | DRUG | Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial. |
| Treatment of Physician's Choice | DRUG | Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC. |
| Low dose cyclophosphamide | DRUG | Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation. |
| Interferon Inoculation | DRUG | Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation. |
| Interferon-alpha-2b | BIOLOGICAL | Low dose given in the vaccine site to boost the immune response |
Inclusion Criteria: 1. Be ≥ 18 years of age. 2. Have signed informed consent. 3. Have histological confirmation of breast cancer with either locally recurrent unresectable and/or metastatic lesions, and have failed prior therapy: * Patients with persistent disease and local recurrence must not ...
Top 20 of 87 competitors
SV-BR-1-GM is being developed for the treatment of breast cancer, including metastatic breast cancer and locally recurrent breast cancer. It is an investigational therapy studied in patients with advanced or metastatic disease, and it is also being evaluated in combination with a checkpoint inhibitor in a Phase 3 regimen.
SV-BR-1-GM is developed by BriaCell Therapeutics Corp., which trades under the ticker BCTX. The company is advancing the asset as part of its breast cancer program, including the Bria-IMT regimen evaluated in a Phase 3 study in advanced metastatic breast cancer.
SV-BR-1-GM is in Phase 3 development. The Phase 3 trial NCT06072612 is evaluating the Bria-IMT regimen and a checkpoint inhibitor versus physicians' choice in advanced metastatic breast cancer, and it is currently recruiting participants in the United States.
SV-BR-1-GM has been studied in three registered trials. The Phase 3 study NCT06072612 is recruiting 404 patients with advanced metastatic breast cancer. The completed Phase 1 studies NCT03328026, which combined SV-BR-1-GM with retifanlimab in 36 patients, and NCT03066947, which enrolled 24 patients with metastatic or locally recurrent breast cancer.
SV-BR-1-GM is not approved and remains an investigational therapy in clinical development. Its most advanced study is the Phase 3 trial NCT06072612, which is recruiting patients with advanced metastatic breast cancer and compares the Bria-IMT regimen plus a checkpoint inhibitor against physicians' choice.
Yes, SV-BR-1-GM development is biomarker selected, meaning trial enrollment is guided by a biomarker rather than an unselected patient population. The Phase 3 study NCT06072612 is randomized and controlled, evaluating the Bria-IMT regimen and a checkpoint inhibitor versus physicians' choice in advanced metastatic breast cancer.